```html

James Disease (Hodgkin Lymphoma) – A Patient‑Friendly Guide

Overview

James disease is a lay‑term that historically referred to the classic presentation of **Hodgkin lymphoma (HL)** – a type of cancer that originates in the lymphatic system. The name honors Dr. Thomas James, a 19th‑century physician who first described the characteristic painless swelling of lymph nodes in the neck and chest.

HL accounts for about 10% of all lymphomas and roughly 0.5% of all cancers worldwide. In the United States, the CDC estimates ~8,500 new cases each year, with a median age at diagnosis of 35 years for males and 40 years for females.

The disease can affect anyone, but it is most common in:

• Young adults (15‑35 years).
• Older adults (>55 years), where a second peak occurs.
• People of European descent, who have a slightly higher incidence than other ethnic groups.

Symptoms

Symptoms often develop slowly and can mimic common infections, which is why many patients notice them only after a routine physical exam. Below is a comprehensive list with brief explanations.

Typical (Classic) Symptoms

• Painless swelling of lymph nodes – most often in the neck, under the arms, or above the clavicle.
• Fever – low‑grade, often occurring in the evening.
• Night sweats – soaking enough to dampen clothing or sheets.
• Unexplained weight loss – >10 % of body weight over 6 months.
• Itching (pruritus) – generalized or localized, sometimes severe.

Other Possible Manifestations

• Fatigue or malaise – persistent tiredness not relieved by rest.
• Cough, shortness of breath, or chest pain – when mediastinal (chest) lymph nodes enlarge.
• Difficulty swallowing – due to compression of the esophagus.
• Abdominal swelling or pain – from enlarged nodes in the abdomen or spleen.
• Bone pain – uncommon but may signal disease spread.
• Enlarged spleen or liver – may be felt as a fullness under the rib cage.

If any of these symptoms persist for more than a few weeks, especially a combination of fever, night sweats, and weight loss (known as “B‑symptoms”), see a healthcare professional promptly.

Causes and Risk Factors

The exact cause of Hodgkin lymphoma is not fully understood, but several factors increase the likelihood of developing the disease.

Known Risk Factors

• Age – the bimodal distribution (young adulthood and later life) suggests age‑related immune changes.
• Sex – slightly more common in males.
• Family history – having a first‑degree relative with HL raises risk 2‑3 fold.
• Epstein‑Barr virus (EBV) infection – EBV DNA is found in Reed‑Stenberg cells of ~30‑50% of cases, especially in mixed‑cellularity and lymphocyte‑depleted subtypes.
• Human immunodeficiency virus (HIV) – immunosuppression predisposes to HL, often with aggressive presentation.
• Autoimmune diseases – such as rheumatoid arthritis or systemic lupus erythematosus.
• Previous radiation exposure – especially childhood or young‑adult exposure to therapeutic radiation.
• Occupational exposures – to chemicals like petrochemicals, pesticides, or some solvents (data still emerging).

What Is Not a Cause

There is no convincing evidence that diet, smoking, or alcohol directly cause HL, although they can affect overall immune health.

Diagnosis

Diagnosing Hodgkin lymphoma involves a stepwise approach that combines clinical evaluation, imaging, and tissue sampling.

Initial Evaluation

• Medical history & physical exam – focuses on lymph node distribution, B‑symptoms, and organ involvement.
• Blood tests – complete blood count (CBC), erythrocyte sedimentation rate (ESR), liver function, and lactate dehydrogenase (LDH) to gauge disease activity.

Imaging Studies

• Chest X‑ray – quick look for mediastinal mass.
• Computed Tomography (CT) scan – detailed view of nodal and extranodal disease in neck, chest, abdomen, and pelvis.
• Positron Emission Tomography (PET) scan – combined PET/CT is the gold standard for staging and assessing response to therapy (captures metabolic activity of lymphoma cells).
• MRI – used when assessing central nervous system involvement or when radiation exposure should be minimized.

Definitive Tissue Diagnosis

The only way to confirm HL is to examine a lymph node or tissue sample under a microscope.

• Excisional biopsy – removal of an entire lymph node (preferred).
• Core needle biopsy – sometimes used when surgery is high risk.
• Fine‑needle aspiration (FNA) – generally insufficient for HL because the characteristic Reed‑Stenberg cells can be missed.

Pathologists look for the hallmark **Reed‑Sternberg cells** (large, binucleated or multinucleated cells with an “owl’s‑eye” appearance) and classify the disease into one of several subtypes (e.g., nodular‑sclerosing, mixed cellularity, lymphocyte‑rich, lymphocyte‑depleted) which can influence treatment decisions.

Staging

Staging follows the **Ann Arbor system** and incorporates PET/CT findings:

• Stage I – involvement of a single lymph node region or a single extralymphatic site.
• Stage II – two or more lymph node regions on the same side of the diaphragm.
• Stage III – lymph node regions on both sides of the diaphragm.
• Stage IV – disseminated involvement of one or more extralymphatic organs (e.g., bone marrow, liver).

Each stage is further labeled “A” (no B‑symptoms) or “B” (presence of B‑symptoms).

Treatment Options

Treatment is highly effective; the 5‑year overall survival in the United States exceeds 85 % for all stages combined, according to the American Cancer Society. Therapy is tailored to disease stage, subtype, patient age, and comorbidities.

First‑Line Therapy

• Combination chemotherapy – most regimens include ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). ABVD is the standard for early‑stage disease and many advanced cases.
• Escalated BEACOPP – used for high‑risk advanced disease; more intensive but higher remission rates.
• Radiation therapy (RT) – involved‑field or involved‑site RT (20‑30 Gy) is added for stage I‑II disease or residual masses after chemotherapy.
• Targeted agents – Brentuximab vedotin (anti‑CD30 antibody‑drug conjugate) is approved for relapse and now incorporated in frontline regimens for some high‑risk patients.
• Immunotherapy – checkpoint inhibitors (nivolumab, pembrolizumab) are options for relapsed/refractory HL after chemotherapy and brentuximab.

Second‑Line (Relapsed or Refractory) Therapy

• High‑dose chemotherapy followed by autologous stem‑cell transplant (ASCT) – standard for patients who respond to salvage chemotherapy.
• Allogeneic stem‑cell transplant – considered in select cases, especially when there is a donor match.
• Clinical trials – many ongoing studies explore novel agents (e.g., antibody‑drug conjugates, CAR‑T cells).

Supportive & Lifestyle Measures

• Growth factor support (e.g., G‑CSF) to reduce neutropenia.
• Anti‑emetics for nausea from chemotherapy.
• Vaccinations – avoid live vaccines during immunosuppression; keep flu and COVID‑19 vaccines up‑to‑date.
• Nutrition – high‑protein, calorie‑dense diet to maintain weight.
• Physical activity – gentle walking or yoga as tolerated to preserve muscle mass and reduce fatigue.

Living with James Disease (Hodgkin’s Lymphoma)

Even after successful treatment, many patients face ongoing physical and emotional challenges. Below are practical tips for daily life.

Follow‑Up Care

• Attend all scheduled oncology visits (typically every 3‑6 months for the first 2 years, then annually).
• Have periodic blood work and imaging (PET/CT or CT) as recommended to detect early recurrence.
• Monitor for late effects of therapy—particularly cardiac, pulmonary, and thyroid dysfunction after radiation or certain chemotherapies.

Managing Side Effects

• Fatigue – schedule rest periods, prioritize tasks, and use light‑exercise to boost energy.
• Pain or neuropathy – discuss with your doctor; gabapentin or physical therapy may help.
• Emotional health – consider counseling, support groups (e.g., Lymphoma Research Foundation), or mindfulness practices.
• Fertility concerns – consult a reproductive specialist before treatment; options include sperm banking or egg/embryo freezing.

Practical Lifestyle Adjustments

• Maintain a balanced diet rich in fruits, vegetables, whole grains, and lean protein.
• Stay hydrated; aim for ≥ 2 L of water daily unless restricted.
• Limit alcohol consumption (≤ 1 drink per day for women, ≤ 2 for men) as it may exacerbate liver toxicity.
• Avoid smoking; nicotine compounds can increase the risk of secondary cancers.
• Use sunscreen daily—radiation therapy can increase skin cancer risk.

Prevention

Because the precise cause of Hodgkin lymphoma is unknown, primary prevention is challenging. However, steps that support a healthy immune system may lower risk:

• Vaccinate against Epstein‑Barr virus where available (research ongoing) and keep up with routine vaccines.
• Practice safe sex and avoid sharing needles to reduce HIV infection risk.
• Control chronic infections (e.g., hepatitis C) that can impair immunity.
• Minimize unnecessary radiation exposure—discuss risks of diagnostic imaging with physicians.
• Adopt a healthy lifestyle: regular exercise, balanced diet, adequate sleep, and stress management.

Complications

If left untreated or if disease recurs, Hodgkin lymphoma can lead to serious health problems.

• Organ compression – large mediastinal nodes can obstruct airways or blood vessels.
• Bone marrow failure – causing anemia, infections, or bleeding.
• Secondary cancers – especially after radiation or alkylating chemotherapy (e.g., breast, lung, thyroid).
• Heart or lung damage – from mediastinal radiation.
• Infertility – due to gonadotoxic chemotherapy or pelvic radiation.
• Psychological distress – anxiety, depression, or post‑traumatic stress disorder (PTSD) after cancer diagnosis.

When to Seek Emergency Care

---

For personalized advice, always discuss your situation with a hematologist/oncologist. This guide is for educational purposes and does not replace professional medical care.

References:
1. Mayo Clinic. Hodgkin lymphoma – Symptoms and causes. https://www.mayoclinic.org.
2. National Cancer Institute. Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov.
3. CDC. Lymphoma Statistics. https://www.cdc.gov.
4. WHO. International Agency for Research on Cancer – Lymphoma classification. https://www.iarc.fr.
5. Cleveland Clinic. Hodgkin’s Disease – Diagnosis and Treatment. https://my.clevelandclinic.org.

```